Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide for fracture prevention in postmenopausal women with type 2 diabetes
ChiCTR2000031879Phase 4Not yet recruiting
- Sponsor
- Tongji Hospital, Tongji University School of Medicine
- Start
- May 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of liraglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Tongji Hospital, Tongji University School of Medicine. Primary endpoints: All-site fractures, Bone mineral density and 2 more. Planned start May 2020; status: not yet recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2000031879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031879.